PMDA posts safety notices on Graceptor/tacrolimus mix-ups and BFLUID infusion preparation
「製薬企業からの医薬品の安全使用に関するお知らせ」に「グラセプターカプセルとタクロリムス普通製剤（後発医薬品含む）との取り違え注意のお願い」及び「ビーフリード輸液 調製時及び投与開始前の隔壁開通確認のお願い」を掲載しました
Published: 2026-06-02 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2026-06-02, the Pharmaceuticals and Medical Devices Agency (PMDA) announced the posting of two pharmaceutical-company notices on safe medicine use. They concern avoiding mix-ups between Graceptor capsules and conventional tacrolimus formulations, including generics, and checking that the partition in BFLUID infusion has been opened during preparation and before administration.
Business Impact
Healthcare professionals handling Graceptor capsules, conventional tacrolimus formulations including generics, or BFLUID infusion may find these notices relevant to product identification and infusion preparation and pre-administration checks.
Recommended Action
Review of the official Japanese notices could clarify the products covered and the specific mix-up precautions and partition-opening checks described.